GSK Shares Positive Data for AREXVY, its Respiratory Syncytial Virus (RSV) Older Adult Vaccine, Indicating Protection Over Two RSV Seasons

GSK has announced positive results from its clinical trial of AREXVY, a vaccine for respiratory syncytial virus (RSV) in older adults. The AReSVi-006 phase III trial found that the vaccine provided protection against RSV-lower respiratory tract disease and severe disease over two full RSV seasons, including in participants with underlying medical conditions. Safety and reactogenicity data were c..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 22.
  • textsms

AstraZeneca and Sanofi's Pediatric RSV Antibody Receives Unanimous Backing from FDA Panel

AstraZeneca and Sanofi have received unanimous backing from the FDA’s Antimicrobial Drugs Advisory Committee for their respiratory syncytial virus (RSV) antibody, nirsevimab, for use in the pediatric setting. Nirsevimab is an investigational long-acting antibody that targets and binds to the part of the RSV virus that attaches to the host’s cells. If approved, nirsevimab would become the first i..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 11.
  • textsms